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a b s t r a c t
Neuroblastoma (NB), which arises from embryonic neural crest cells, is the most common extra-cranial
solid tumor of childhood. Approximately half of NB patients manifest bone metastasis accompanied with
bone pain, fractures and bone marrow failure, leading to disturbed quality of life and poor survival.
To study the mechanism of bone metastasis of NB, we established an animal model in which intracardiac
inoculation of the SK-N-AS human NB cells in nude mice developed osteolytic bone metastases with
increased osteoclastogenesis. SK-N-AS cells induced the expression of receptor activator of NF-κB ligand
and osteoclastogenesis in mouse bone marrow cells in the co-culture. SK-N-AS cells expressed COX-2
mRNA and produced substantial amounts of prostaglandin E2 (PGE2). In contrast, the SK-N-DZ and SK-N-
FI human NB cells failed to develop bone metastases, induce osteoclastogenesis, express COX-2 mRNA
and produce PGE2. Immunohistochemical examination of SK-N-AS bone metastasis and subcutaneous
tumor showed strong expression of COX-2. The selective COX-2 inhibitor NS-398 inhibited PGE2
production and suppressed bone metastases with reduced osteoclastogenesis. NS-398 also inhibited
subcutaneous SK-N-AS tumor development with decreased angiogenesis and vascular endothelial
growth factor-A expression. Of interest, metastasis to the adrenal gland, a preferential site for NB
development, was also diminished by NS-398. Our results suggest that COX2/PGE2 axis plays a critical
role in the pathophysiology of osteolytic bone metastases and tumor development of the SK-NS-AS
human NB. Inhibition of angiogenesis by suppressing COX-2/PGE2 may be an effective therapeutic
approach for children with NB.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Neuroblastoma (NB), which arises from embryonal neural crest
cells, is the most common extra-cranial solid tumor of childhood
and accounts for more than 15% of all child cancer death [1,2].
Patients with NB frequently manifest disseminated disease at ﬁrst
visit and prognosis of these patients is poor with 3-year survival
rate less than 40% [1,2]. It has been well-known that bone is one of
the most common target sites of NB spread. More than 60% of
advanced NB patients manifest bone metastases that are radiolo-
gically osteolytic or a mixture of osteolytic and osteoblastic type
[3,4]. Children with bone metastases suffer from complications
including intolerable bone pain, pathological fractures and bone
marrow failure. Currently-available anti-NB therapies are not
satisfactorily effective at treating bone metastases and these
complications. Accordingly, these children show miserable clinical
courses and poor survival rate [5,6]. Therefore, control of bone
metastases is an important goal in the management of infants
with NB [7] and effective therapeutic interventions designed based
on the understanding of the pathophysiology of bone metastasis of
NB have been awaited. However, the mechanism underlying the
preferential metastasis of NB to bone remains poorly understood.
Recent studies suggest that the interactions between cancer
cells and bone microenvironment are critical to the pathophysiol-
ogy of bone metastasis [8,9]. Bone provides a fertile soil for
metastatic cancer cells by releasing growth factors such as
insulin-like growth factors (IGFs) [10] and transforming growth
factor β (TGFβ) [11] as a consequence of osteoclastic bone resorp-
tion during bone remodeling. Cancer cells stimulated by these
bone-derived growth factors consequently produce increased
levels of osteoclast-stimulating factors such as parathyroid
hormone-related protein (PTH-rP) [11] and prostaglandin E2
(PGE2) [12], which in turn further promotes osteoclastic bone
resorption, establishing a vicious cycle between bone-resorbing
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osteoclasts and metastatic cancer cells [8,9]. Contribution of
similar vicious cycle between NB and bone microenvironment
[13] mediated by receptor activator of NF-κB ligand (RANKL)
[14,15] and IGF-1 [16] to the development and progression of NB
bone metastasis has been also suggested.
In the present study, we developed an animal model of NB
bone metastasis to advance our understanding of the mechanism
of bone metastasis. We showed that an inoculation of the SK-N-AS
human NB cells into the left heart ventricle of nude mice caused
osteolytic bone metastases with increased osteoclastogenesis. SK-
N-AS cells expressed COX-2 mRNA and produced substantial
amounts of PGE2. The selective COX-2 inhibitor NS-398 inhibited
PGE2 production and osteolytic bone metastases with reduced
osteoclastic bone resorption and subcutaneous SK-N-AS tumor
enlargement with reduced angiogenesis. These results suggest
that COX-2/PGE2 system plays a critical role in the pathophysiol-
ogy of osteolytic bone metastases and tumor progression of NB.
Inhibition of COX-2/PGE2 is a potential therapeutic intervention for
bone metastases in children with NB.
2. Materials and methods
2.1. Reagents and antibodies
Recombinant human osteoprotegerin (OPG) was purchased
from BioSource International (Camarillo, CA). 1,25-dihydroxyvita-
min D3 (1,25D3) was from BIOMOL International (Plymouth Meet-
ing, PA). Dimethylsulfoxide (DMSO), PGE2, and indomethacin were
obtained from Sigma Chemical Co. (St. Louis, MO). NS-398,
a selective COX-2 inhibitor, was purchased from Cayman Chemical
Co. (Ann Arbor, MI). For in vitro use, indomethacin and NS-398
were reconstituted in DMSO and diluted with culture media. The
ﬁnal concentration of DMSO in the culture media was less
than 0.1%.
Polyclonal rabbit anti-vascular endothelial growth factor-A
(VEGF-A) and polyclonal rabbit anti-proliferation cell nuclear
antigen (PCNA) were from Santa Cruz Biotechnology (Santa Cruz,
CA). Polyclonal rabbit anti-COX-2 and polyclonal rabbit anti-factor
VIII were from Zymed Laboratories, Inc. (South San Francisco, CA).
2.2. Human neuroblastoma cells
Human NB cell lines, SK-N-DZ, SK-N-AS, SK-N-FI, were obtained
from American Type Culture Collection (Rockville, MD). All cells
were maintained in Dulbecco's modiﬁed Eagle minimal essential
medium (DMEM, Life Technologies, Inc., Grand Island, NY) sup-
plemented with 10% fetal calf serum (FCS; Life Technologies, Inc.)
at 37 1C under 5% CO2 in air.
2.3. Tumorigenicity of human NB cell lines
Animal protocols were approved by the Institutional Animal
Care and Use Committee at the University of Texas Health Science
center at San Antonio and were in accordance with the NIH Guide
for the Care and Use of Laboratory Animals. Animals were kept in
our speciﬁc pathogen-free animal facilities. SK-N-DZ, SK-N-AS or
SK-N-FI human NB cells (2.5106) were suspended in 0.1 ml of
phosphate buffered saline (PBS) and inoculated subcutaneously
into the right ﬂank of 4-week-old BALB/c-nu/nu (nude) mice
(National Cancer Institute, Frederick, MD) (Day 0). Tumor volume
was determined weekly based on the calculation suggested by the
National Cancer Institute formula: Volume (cm3)¼(L cm I2 cm)/
2, in which L is the largest diameter, and I is the smallest diameter
of the tumor. Body weight (BW) of mice bearing with or without
NB tumor was measured weekly until sacriﬁce. Subcutaneous (sc)
tumors were excised and their wet weight was determined.
A portion of the tumor tissue was ﬁxed in 10% formalin for
subsequent histological examinations and remaining tissues were
snap-frozen in liquid nitrogen and stored at 80 1C for RNA
extraction.
2.4. Bone metastases of human NB cell lines
Bone metastasis of SK-N-DZ, SK-N-AS or SK-N-FI human NB
cells was studied using a well-characterized animal model we
described previously [17]. Brieﬂy, NB cells (5105) were sus-
pended in 0.1 ml of PBS and injected into the left heart ventricle of
4-week-old nude mice with 27-gauge needle under anesthesia
with pentobarbital (0.05 mg/g body weight) (Day 0). Development
of bone metastases was monitored weekly by X-ray. At 5 weeks,
mice were euthanized and blood was collected for Ca2þ measure-
ment and all bones and soft tissues were harvested and ﬁxed in
formalin for subsequent histological analyses.
2.5. Radiological monitoring of bone metastases
Animals were anesthetized deeply, then x-rayed in a prone
position against the ﬁlm (2227 cm2 X-Omat AR, Eastman Kodak
Co., Rochester, NY) and exposed with X-rays at 35 KVP for 6 s using
a Faxitron radiographic inspection unit (43855A; Faxitron X-ray
Corporation, Buffalo Grove, IL) as described [17]. The radiographs
were scanned and the area of osteolytic lesions was measured
using NIH Image 1.62 and the results were expressed in square
millimeters. The number of bone metastases was also counted in
bilateral femurs and tibiae.
2.6. Ca2þ measurement
Ca2þ concentrations were measured in whole blood using a
Ciba Corning 634 ISE Ca2þ/pH analyzer (Corning Medical and
Scientiﬁc, Medﬁeld, MA) and adjusted using the internal algorithm
of the instrument to pH 7.4 as described previously [18].
2.7. Administration of a selective COX-2 inhibitor NS-398
Three days after the tumor cell inoculation, mice were divided
into two groups, one group of mice received daily intraperitoneal
(ip) injections of 100 ml vehicle (50% v/v DMSO) and another group
of mice received NS-398 (15 mg/kg body weight) [12] until the end
of the experiments.
2.8. Histology
Soft tissues and bones were removed from mice at the time of
sacriﬁce, ﬁxed in 10% buffered formalin for 2 days. Bones were
further decalciﬁed in 14% EDTA solution for 2 weeks at room
temperature with gentle stirring. Subsequently, they were
embedded in parafﬁn and stained with hematoxylin and eosin
(H&E). Tartrate-resistant acid phosphatase (TRAP) staining was
also performed according to the procedure described [12].
2.9. Immunohistochemistry
Parafﬁn sections (5 mm) were deparafﬁnized in xylene and
rehydrated through graded alcohol [100%, 95%, 80% ethanol/
double distilled H2O (v/v)], and then rehydrated in PBS (pH 7.4).
Sections were microwaved in 10 mM trisodium citrate (pH 6.0) for
4 min for antigen retrieval and then endogenous peroxidase
activity was blocked by incubation in 3% H2O2/methanol for
30 min at room temperature. After a 30-min treatment with 10%
normal goat serum diluted in PBS, sections were incubated
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overnight at 4 1C with a 1:100–200 dilution of anti-VEGF-A, anti-
PCNA, anti-COX-2 or anti-factor VIII antibody. Antibodies were
diluted with PBS containing 1% normal goat serum. Normal rabbit
IgG was used as negative control. The specimens were then rinsed
and incubated with biotinylated anti-rabbit IgG (Vector Labora-
tories, Burlingame, CA) for 30 min at room temperature. Next, they
were stained according to the avidin–biotin-peroxide complex
(ABC) method using a commercial kit (Vectastain Elite ABC; Vector
Laboratories). Subsequently, the specimens were counterstained
with hematoxylin (VEGF-A, COX-2, and factor-VIII).
2.10. Co-cultures of human NB Cells and mouse bone marrow cells
Mouse bone marrow cells (BMCs) and spleen cells were
isolated from 4- to 8-week-old male C57BL mice (Harlan, India-
napolis, IN) as described [19,20]. Brieﬂy, femurs and tibiae were
excised aseptically, cut off both ends. The marrow cavity of femurs
and tibiae was ﬂushed with α-minimum essential medium (αMEM,
Life Technologies, Inc.) and then BMCs were collected. The col-
lected BMCs (5105 cells/48-well for TRAP stain, 4106 cells/6-
well for RNA extraction) were co-cultured with NB cells (0.5104
cells/48-well for TRAP stain, 4104 cells/6-well for RNA extrac-
tion) in αMEM containing 10% FCS in 48-well plates (0.2 ml/well)
or 6-well plates (1.2 ml/well) for 6 days. As a positive control,
BMCs were cultured in the presence of 108 M 1,25D3.
Spleen cells were obtained from splenic tissues aseptically
collected from mice. NB cells (0.5104 cells/well in a 48-well
plate) were co-cultured with spleen cells (5105 cells/well in a
48-well plate) in the presence or absence of bone marrow stromal
cells (5105 cells/well) for 8 days. The cultures were fed every
3 days by replacing a half of the spent mediumwith fresh medium.
At the end of cultures, conditioned media were harvested and the
cells adhering to the well surface were stained for TRAP using
commercially available kits (Leukocyte acid phosphatase A kit,
Sigma) or extracted RNA. TRAP-positive multinucleated cells (TRAP
(þ) MNCs) containing three or more nuclei per cell were counted
as osteoclast-like cells (OC).
2.11. Prostaglandin E2 (PGE2) assay
Culture media were harvested at the end of experiments and
frozen at 80 1C. Concentrations of PGE2 in the culture media
were determined using an EIA kit (Cayman Chemical Co.) accord-
ing the protocol provided by the manufacture. Measurements
were made in triplicate wells.
2.12. Reverse transcribed polymerase chain reaction (RT-PCR)
Total RNA was isolated using the TRI reagent (Sigma Chemical
Co.) according to the manufacture's protocol. First-strand comple-
mentary DNAs (cDNAs) were synthesized from total RNA (1 mg) in
20 ml of reaction mixture containing oligo (dT) primer and super-
script reverse transcriptase (Invitrogen, Carlsbad, CA). One micro-
liter of this reaction was ampliﬁed using PCR primer sets for
mouse RANKL [21], mouse OPG [21], mouse glyceraldehydes 3-
phosphate dehydrogenase (GAPDH) [21], human COX-1 [22],
human COX-2 [23], human VEGF-A [24], and human GAPDH [21]
according to the manufacture's instruction (Invitrogen). The PCR
products were analyzed by agarose gel electrophoresis and visua-
lized by ethidium bromide staining under UV light.
2.13. Western analysis
After overnight serum starvation, cells were washed three
times with ice-cold PBS, and lyzed in the lysis buffer [20 mM
HEPES (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1.5 mM MgCI2, 10%
glycerol, 1% Triton X-100, 10 μg/ml aprotinin, 10 μg/ml leupeptin,
1 mM PMSF, 0.1 mM sodium orthovanadate]. The cell lysates were
boiled in SDS sample buffer containing 0.5 M beta-mercaptoetha-
nol, separated by SDS-PAGE, transferred to nitrocellulose mem-
branes and immunoblotted with anti-COX-2 antibody as described
[12]. Separated proteins were visualized with horseradish perox-
idase coupled with protein A (Kirkegaard & Perry laboratories, Inc.,
Gaithersburg, MD) with enhancement by chemiluminescence
using ECL Western Blotting Detection Reagent (Amersham
Bioscience Corp., Piscataway, NJ).
2.14. Statistical analysis
Results are expressed as the mean7SE. Data were analyzed by
either one-factor ANOVA followed by Turkey-Kramer post-hoc
test, Mann-Whitney U test, or unpaired Student's t test. P values
ofo0.05 were considered signiﬁcant. All statistical analyses were
carried out using Statview ver 5 (SAS Institute Inc., Berkeley, CA).
3. Results
3.1. Establishment of an animal model of bone metastasis of Human
NB
Three human NB cell lines (SK-N-DZ, SK-N-AS, and SK-N-FI)
developed tumors after sc inoculation. However, these sc tumors
failed to develop radiologically-detectable bone metastases. His-
tological examination revealed no metastases to soft tissue organs
and bones even at 12 weeks. Accordingly, we inoculated these NB
cells into the left ventricle of the heart, which is a well-established
technique to develop bone metastases [17]. Among three NB cell
lines tested, only SK-N-AS cells reproducibly developed discernible
osteolytic lesions in the limbs on X-ray over a period of 5–6 weeks
(Fig. 1A). Some mice (40%) showed hind limb paralysis with
metastases to spine and spinal cord. Mice inoculated with SK-N-AS
cells also demonstrated metastases to adrenal gland, kidney and
lung but not liver, with a decrease in body weight, an average of
15.5% loss compared to control mice. Histological examination
demonstrated extensive tumor colonization in the bone marrow
cavity and destruction of trabecular bone (Fig. 1B). Increased
numbers of TRAP (þ) osteoclasts were observed along the endo-
steal bone surface (Fig. 1C). Blood Ca2þ concentration remained
normal in mice received sc or heart injection of SK-N-AS cells (sc
injection: 1.2870.06 mM, heart-injection: 1.2670.05 mM, control;
1.2970.03 mM, n¼5). SK-N-A-DZ and SK-N-FI cells rarely devel-
oped bone metastases following heart inoculation.
3.2. TRAP (þ) MNC formation in the co-cultures of NB cells with
mouse BMCs
To determine the mechanism of increased osteoclasts in the
bone metastases of SK-N-AS cells, we examined whether SK-N-AS
cells supported osteoclast formation in the co-cultures with mouse
BMCs. We found that TRAP (þ) MNCs formed in the co-cultures of
SK-N-AS cells and mouse BMCs (Fig. 2A and B). These TRAP (þ)
MNCs cells formed resorption pits on dentine slices (data not
shown). In contrast, co-cultures of mouse BMCs with SK-N-DZ or
SK-N-FI cells that failed to develop bone metastases showed no
induction of osteoclastogenesis (Fig. 2A). Since receptor activator
of NF-κB ligand (RANKL) expressed in marrow stromal cells plays a
central role in osteoclastogenesis [25], we next examined whether
SK-N-AS cells induced RANKL expression in mouse BMCs. RT-PCR
analysis showed an induction of RANKL mRNA expression
in mouse BMCs co-cultured with SK-N-AS cells (Fig. 2C). The
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conditioned medium (CM) harvested from SK-N-AS cells also
induced mRANKL mRNA expression in mouse BMCs (Fig. 2C).
Consistent with up-regulation of mRANKL in the co-cultures of
mouse BMCs and SK-N-AS cells, osteoprotegerin (OPG), a natural
antagonist of RANKL [25], reduced TRAP (þ) MNC formation in the
co-cultures in a dose-dependent manner (Fig. 2D). SK-N-AS cells
did not change mRNA expression of OPG in mouse BMCs. These
results collectively suggest that a soluble factor produced by SK-N-
MS cells induces RANKL expression in mouse BMCs, leading to an
induction of osteoclastogenesis.
x200x40
Fig. 1. Bone metastasis of the SK-N-AS human NB cell line. (A) Radiograph of hindlimbs of mouse bearing SK-N-AS tumors 40 days after intracardiac inoculation of 5105
SK-N-AS tumor cells. Osteolytic bone metastases are indicated by arrows. (B) Histological pictures of bone metastases stained with H&E (40 ). The bone marrow cavity was
occupied by SK-N-AS tumor and trabecular bones were completely destroyed. (C) Histological pictures of bone metastases stained with TRAP (200 ). Histological sections
were made using proximal tibial midsection of mice bearing SK-N-AS cells. SK-N-AS tumor cells (T) extensively colonized bone marrow cavity with increased numbers of OCs
(arrows) along the endosteal surface of bone.
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Fig. 2. TRAP (þ) MNCs formation in the co-cultures of human NB cells and mouse BMCs. Mouse BMCs (5105 cells/well) were co-cultured with or without () SK-N-DZ,
SK-N-AS or SK-N-FI human NB cells (0.5104 cells/well) without addition of osteoclastogenic cytokine for 6 days. 1,25D3 (108 M) served as positive control. (A) Formation
of TRAP (þ) MNCs. Data are expressed as mean7SE (n¼3). There was no TRAP (þ) MNC formation in the cultures of BMCs alone and co-cultures of BMCs and SK-N-DZ or
SK-N-FI cells in the absence of osteoclastogenic cytokine. In contrast, the co-cultures of BMCs and SK-N-AS cells produced TRAP (þ) MNC in the absence of osteoclastogenic
cytokine to an equivalent level to that of 1,25D3 (108 M). *Signiﬁcantly different from SK-N-DZ and SK-N-FI (po0.01). (B) Representative pictures of TRAP (þ) MNCs formed
in the co-cultures of BMCs and SK-N-AS cells. (C) RT-PCR analysis of RANKL expression in mouse BMCs. Mouse BMCs (4106 cells/well) were co-cultured with or without SK-
N-AS cells (4104 cells/well) or cultured in the presence of the conditioned medium from SK-N-AS cells (SK-N-AS CM, 20% v/v) for 6 days. Mouse BMCs co-cultured with SK-
N-AS cells or treated with SK-N-AS CM showed increased mRANKL mRNA expression. mRANKL was undetectable in untreated BMCs. 1,25D3 served as positive control.
(D) Effects of OPG on TRAP (þ) MNC formation in the co-cultures of SK-N-AS cells and mouse BMCs. Mouse BMCs (5105 cells/well) were co-cultured with SK-N-AS cells
(0.5104 cells/well) in the presence of OPG for 6 days and TRAP (þ) MNCs were counted. OPG inhibited TRAP formation in mouse BM cells induced by SK-N-AS cells in a
dose-dependent manner. Data are expressed as mean7SE (n¼3). *Signiﬁcantly different from untreated group (po0.01).
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3.3. Expression of COX-2 and PGE2 production in SK-N-AS cells
To search for a soluble factor responsible for the induction of
osteoclastogenesis, we examined mRNA expression of several
known osteoclastogenic cytokines in SK-N-AS cells by RT-PCR. As
shown in Fig. 3A, SK-N-AS cells expressed mRNA of parathyroid
hormone-related protein (PTH-rP), interleukin-1 α (IL-1α), IL-1β and
IL-11 but not tumor necrosis factor α (TNFα) and IL-6. Of note, COX-2
mRNA expression was observed only in SK-N-AS cells in three
human NB cell lines studied here. COX-2 is a rate-limiting enzyme
in PG synthesis [26]. PGs, especially PGE2, are known as potent
osteoclastogenic factors [12]. Western analysis also showed that
only SK-N-AS cells expressed COX-2 protein (Fig. 3B). Furthermore,
EIA measurement demonstrated that SK-N-AS cells produced larger
amounts of PGE2 than SK-N-DZ and SK-N-FI cells (Fig. 3C). Immu-
nohistochemical examination showed that sc tumor and bone
metastases of SK-N-AS were positive for COX-2 (Fig. 3D). Taken
together, these results suggest that PGE2 produced by SK-N-AS cells
plays a role in increased osteoclastogenesis in the co-cultures.
3.4. Effect of indomethacin and NS-398 on TRAP (þ) MNC formation
in co-cultures
To verify the role of COX-2/PGE2 in the TRAP (þ) MNC
formation in the co-cultures, the effects of a non-selective COX
inhibitor indomethacin and a selective COX-2 inhibitor NS-398
were examined. Both agents inhibited PGE2 production (Fig. 4A)
and TRAP (þ) MNC formation (Fig. 4B and C) in the co-cultures.
Addition of 106 M PGE2 to the NS-398-treated co-cultures
restored the TRAP (þ) MNC formation, suggesting that the effects
of NS-398 were not due to toxicity (data not shown).
3.5. Effects of NS-398 on SK-N-AS bone metastasis
Next, we examined whether COX-2 played a role in bone
metastasis. As shown in Fig. 7A, control mice developed extensive
osteolytic bone metastases 5 weeks after intracardiac inoculation
of SK-N-AS cell inoculation. Treatment with NS-398 (15 mg/kg
body weight) markedly reduced osteolytic lesions on radiographs
(Figs. 5A and B; 4.1270.65 mm2 (untreated) vs 1.5370.71 mm2
(NS-398); po0.05). The number of bone metastases also signiﬁ-
cantly reduced in NS-398-treated mice compared to untreated
mice (Fig. 5C; 3.870.2 (untreated) vs 1.870.8 (NS-398); po0.05).
Histological examination revealed that NS-398 markedly reduced
the number of OCs compared with untreated group (Fig. 5D).
NS-398 also signiﬁcantly prevented body weight loss in tumor-
bearing mice (17.7270.82 g (untreated) vs 21.04 70.82 g (NS-398);
po0.05).
3.6. Effect of NS-398 on subcutaneous SK-N-AS tumor formation and
angiogenesis
We next investigated the effects of NS-398 on subcutaneous
SK-N-AS tumor formation. Daily treatment with NS-398 (15 mg/kg
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Fig. 3. (A) RT-PCR analysis of the expression of osteoclastogenic cytokine mRNA in SK-N-AS, SK-N-DZ, SK-N-FI human NB cells and a variety of human tumors. MG-63:
human osteosarcoma cell line; MDA-231: estrogen-independent human breast cancer cell line; MCF-7: estrogen-dependent human breast cancer cell line. Note that COX-2
was expressed in SK-N-AS cells but not SK-N-DZ and SK-N-FI cells. (B) Western analysis of COX-2 expression in SK-N-AS, SK-N-DZ, SK-N-FI human NB cells. SK-N-AS cells
showed strong COX-2 expression. (C): PGE2 production in SK-N-AS, SK-N-DZ, SK-N-FI human NB cells in culture. Conﬂuent cells were cultured in serum-free medium for 48 h
and CMs were harvested and determined PGE2 concentrations using an EIA kit as described in the text. Data were normalized for cell number. Data are expressed as
mean7SE (n¼3). *Signiﬁcantly greater than SK-N-DZ and SK-N-FI cultures (po0.01). (D): COX-2 expression in SK-N-AS tumor in vivo. Parafﬁn-embedded specimens from sc
tumors and bone metastases of SK-N-AS were stained with H&E and anti-COX-2 antibody as described in the text. COX-2 expression was detected in both sc tumor and bone
metastasis. T: tumor; Negative control: no primary antibody. Original magniﬁcation, 200 .
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body weight) signiﬁcantly inhibited tumor enlargement as deter-
mined by volume (Fig. 6A). Average tumor wet weight at sacriﬁce
was 9.4472.60 g in untreated mice and 1.2270.69 g in NS-398-
treated mice (Fig. 6B). SK-N-AS cell proliferation in the subcuta-
neous tumor determined by immunohistochemical staining for
PCNA was not apparently different between untreated and NS-
398-treated tumors (data not shown). In addition, NS-398 had no
effects on the cell proliferation of SK-N-AS cells in culture at
concentrations as high as 200 μM assessed by MTT assay (data not
shown). These results suggest that the inhibition of subcutaneous
SK-N-AS tumor formation by NS-398 is not due to direct inhibition
of SK-N-AS cell proliferation.
To investigate the mechanism by which NS-398 reduced tumor
development independent of cell proliferation, we examined the
effects of NS-398 on tumor-associated angiogenesis. Vasculariza-
tion was identiﬁed by staining with an anti-factor VIII antibody.
Representative sections from untreated and NS-398-treated
tumors are shown in Fig. 6C. Blood vessels in the tumors of
untreated mice showed intensive staining of factor VIII, indicating
well-developed vascular networks. In contrast, there were few
blood vessels in the tumors of NS-398-treated mice. To determine
whether the inhibitory effects of NS-398 on the angiogenesis was
due to the suppression of VEGF, a powerful stimulator of angio-
genesis, the expression of VEGF-A was studied by immunohisto-
chemistry. VEGF-A expression was reduced in NS-398-treated
mice compared with untreated mice (Fig. 6C). RT-PCR displayed
that NS-398 inhibited the expression of VEGF-A mRNA, in parti-
cular VEGF-A121 isoform in SK-N-AS tumor (Fig. 6D). We also found
that SK-N-AS cells expressed PGE2 receptors, EP1, EP2, EP3 and EP4
and PGE2 increased VEGF mRNA expression by RT-PCR in SK-N-AS
cells (data not shown). These results suggest that PGE2 is an
autocrine stimulator of angiogenesis via up-regulation of VEGF-A
expression in SK-N-AS cells.
3.7. Effects of NS-398 on SK-N-AS adrenal gland metastasis
Since NB tumor arises in adrenal gland [1,2] and adrenal gland
is one of the preferential sites of metastasis in the heart injection
model [27], we next examined the effects of NS-398 on adrenal
gland metastases of SK-N-AS cells following intracardiac inocula-
tion. Although not statistically signiﬁcant, NS-398 decreased the
number of adrenal gland metastases (1.870.2 (untreated) vs
1.070.4 (NS-398)) on histological sections (Fig. 7A), while organ
weight of adrenal gland including metastatic SK-N-AS tumors in
NS-398-treated mice was signiﬁcantly lesser than untreated mice
(0.17870.064 g (untreated) vs 0.048270.023 g (NS-398);
po0.05) (Fig. 7B). These results suggest that NS-398 inhibited
metastases not only to bone but also adrenal glands. Histological
examination of gastric mucosa and liver showed no toxic effects of
NS-398 in mice during the experiments.
3.8. Contribution of PTH-rP to SK-N-AS bone metastasis
PTH-rP is a potent osteoclastogenic factor and has long been
implicated in breast cancer metastasis to bone [8,9]. SK-N-AS cells
express PTH-rP mRNA. However, the levels of PTH-rP protein
produced by SK-N-AS cells in culture were low compared with
the MDA-MB-231 human breast cancer cells that cause extensive
bone metastases (basal level: 0.5170.05 pmol/105 SK-N-AS cells
vs 1.4670.14 pmol/105 MDA-MB-231 cells). TGFβ, which is a
potent stimulator of PTH-rP production [8,9], did not increase
PTH-rP production in SK-N-AS cells in culture (PTH-rP production
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Fig. 4. (A) Effects of COX inhibitors on PGE2 production in the co-cultures of mouse BMCs and SK-N-AS cells. Indomethacin (Indo) and NS-398 signiﬁcantly suppressed PGE2
production in the co-cultures. Mouse BMCs (5105 cells/well) were co-cultured with SK-N-AS cells (0.5104 cells/well) in the absence or presence of indomethacin
(106 M) or NS-398 (106 M) for 6 days. At the end of the experiments, CM were harvested and measured for PGE2 concentrations (A). Remaining adherent cells were then
stained for TRAP (B). (B) Effects of COX inhibitors on TRAP (þ) MNC formation in the co-cultures of mouse BMCs and SK-N-AS cells. Indomethacin and NS-398 inhibited PGE2
production and TRAP (þ) MNC formation in the co-cultures. Data are expressed as mean7SE (n¼3). *Signiﬁcantly different from BMC (po0.01). **Signiﬁcantly different
from control (po0.01). (C) Representative pictures of TRAP (þ) MNC formation in the co-cultures of mouse BMCs and SK-N-AS cells in the absence (top) or presence of
indomethacin (bottom left) or NS-398 (bottom right).
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in the presence of 10 ng/ml TGFβ: 0.7570.04 pmol/105 SK-N-AS
cells vs 3.8470.29 pmol/105 MDA-MB-231 cells). Furthermore,
SK-N-FI cells that had no capacity to develop bone metastases
following intracardiac inoculation also expressed PTH-rP mRNA by
RT-PCR. Therefore, it is unlikely that PTH-rP contributes to the
osteolytic bone metastases of SK-N-AS NB.
4. Discussion
In the present study, we have shown that, of the three human
NB cell lines examined, only the SK-N-AS human NB cell line
reproducibly developed radiologically and histologically discern-
ible osteolytic bone metastases following intracardiac inoculation
in nude mice. Histological examination demonstrated that there
were numerous TRAP-positive osteoclasts present along the endo-
steal surface of eroded bone in the SK-N-AS bone metastases. In
the co-cultures with mouse BMCs, SK-N-AS cells induced TRAP (þ)
MNC formation in the absence of osteoclastogenic factor. The
induction was RANKL-dependent, since mRANKL mRNA expres-
sion was induced in mouse BMCs and TRAP (þ) MNC formation
was decreased by OPG in the co-culture with SK-NAS cells. On the
other hand, SK-N-DZ and SK-N-FI cells that failed to develop bone
metastases did not induce TRAP (þ) MNC formation in the co-
cultures with mouse BMCs. These results suggest that SK-N-AS
cells possess the capacity to cause osteolytic bone metastases
accompanied with RANKL-dependent osteoclastogenesis. Subse-
quently, we attempted to understand this capacity at molecular
levels. The result that SK-N-AS CM increased TRAP (þ) MNC
formation in mouse BMCs suggests that SK-N-AS cells produce a
soluble osteoclastogenic factor. We found that SK-N-AS cells
strongly expressed COX-2 and produced substantial levels of
PGE2, while non-bone metastatic SK-N-DZ and SK-N-FI cells did
not express COX-2 and produced little PGE2. Furthermore, the
selective COX-2 inhibitor NS-398 signiﬁcantly reduced bone
metastases and osteoclastogenesis in vivo and in vitro. Taken
together, these experimental data suggest that COX-2 expression
and consequent PGE2 production are responsible for causing bone
metastases with increased osteoclastogenesis in SK-N-AS human
NB cells. Consistent with our results, it was reported that elevated
COX-2 expression and PGE2 production and induction of apoptosis
and inhibition of tumor growth in vivo by the nonsteroidal anti-
inﬂammatory drugs in NB [28,29]. Thus, we show here an estab-
lishment of a reproducible animal model of osteolytic bone
metastases of human NB in which COX-2/PGE2 plays a critical
role. We believe that this model leads us to deepen our under-
standing of the mechanism of bone metastasis of NB.
The animal model described here is also expected to lead us to
design mechanism-based therapeutic interventions for bone
metastases of NB. In this context, it is notable that the selective
COX-2 inhibitor NS-398, which is known to selectively inhibit
COX-2 without affecting COX-1 activity [30], inhibited bone
metastases of SK-N-AS cells. Consistent with the results described
here, we reported that NS-398 signiﬁcantly reduced osteolytic
bone metastases of MDA-MB-231 human breast cancer cells [12].
Moreover, Sabino et al. [31] described that NS-398 not only
decreased 2472 sarcoma colonization in bone and bone destruc-
tion but also bone pain associated with tumor growth, suggesting
an additional potential beneﬁcial effect of COX-2 inhibitors for NB
treatment. Bone pain is one of the most common and devastating
complications in bone metastases in children with NB [32].
Another notable ﬁnding in our study is that NS-398 inhibited
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(control) or NS-398 (15 mg/kg. ip). Five weeks after tumor inoculation, radiographs were taken and bones were harvested for histological analyses. (A) Representative
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not only bone metastases but also adrenal metastases. Adrenal
gland is a preferential site for NB to initiate and expand, which
leads to death [1,2]. Thus, selective COX-2 inhibitors may have
beneﬁcial effects on not only quality of life but survival in infants
with NB. Clinical studies also reported that the selective COX-2
inhibitor celecoxib prevented the occurrence of colorectal adeno-
mas [33] and showed some therapeutic effects in patients with
breast [34], head and neck [35], cervical [36], non-small cell lung
[37], colorectal [38] and ovarian cancer [39]. Of note, a recent
clinical study described that oral celecoxib prevented the progres-
sion of neuroblastoma [40]. Further experimental and clinical
studies are needed to verify the beneﬁcial effects of selective
COX-2 inhibitors for the treatment of infants with NB. The NB
model described here would provide with a suitable preclinical
model to conduct these studies.
Since the selective COX-2 inhibitor NS-398 did not inhibit the
proliferation of SK-N-AS cells in vivo and in vitro, we reasoned that
the agent suppressed tumor-associated angiogenesis. Angiogen-
esis is essential for tumor cells to initiate, grow, survive, invade
and spread [41]. VEGF, a speciﬁc mitogen for neovascularization,
is a major factor in the promotion of tumor angiogenesis and
growth of human cancers [42]. The importance of VEGF expression
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associated with angiogenesis in tumor behavior is also suggested
in NB [43]. Several recent experimental studies have reported that
COX-2 inhibitors inhibit tumor angiogenesis through down-
regulation of VEGF expression, thereby suppressing tumor growth
in breast [44], colorectal [45] and pancreatic cancer [46]. Further-
more, it has been shown that celecoxib combined with irinotecan
inhibits the growth of neuroblastoma xenografts through induc-
tion of apoptosis and suppression of angiogenesis with decreased
VEGF expression [47]. Consistent with these previous studies, we
found that NS-398 decreased vascularization and VEGF-A expres-
sion in subcutaneous SK-N-AS tumors. COX-2/PGE2 is a well-
known stimulator of angiogenesis [44–46]. Collectively, these
results suggest that the inhibition by NS-398 of subcutaneous
tumor growth and bone metastases of SK-N-AS NB is due to the
suppression of VEGF and angiogenesis.
Based on the pathophysiology bone metastasis [8,9], inhibition
of osteoclastic bone resorption is a mechanism-based treatment
for bone metastases regardless of cancer type. Bisphosphonates
(BPs), which are potent and speciﬁc inhibitors of osteoclastic bone
resorption, have been widely used for the treatment of bone
metastases [48]. An experimental animal study reported that the
BP ibandronate inhibited osteolytic bone lesions developed after
intra-femoral injection of NB cells [49]. However, caution is
required for the use of BPs for the treatment of bone metastases
of NB children, since administration of BP may have adverse
effects on skeletal growth in growing infants [50]. In this context,
COX-2 inhibitors could be an alternative agent in the management
of bone metastases in infants with NB with less adverse effects on
skeletal growth.
In summary, we have established an animal model of human
NB bone metastasis in which COX-2/PGE2 plays a critical role. We
provide pre-clinical data supporting the use of COX-2 inhibitors in
the treatment of bone metastases in NB.
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